Abstract 1823: Preclinical efficacy and safety of CS5007, an EGFR×HER3 dual-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: CStone Pharmaceuticals (China)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148658048
Cites:
Cited by:
Related to: